JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - PROKIDNEY CORP
Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining me today. And it's my pleasure to have the ProKidney team with me. To my direct right, Bruce Culleton, CEO. To his right is James Coulston, CFO. And to James' right is Anthony Conway, VP, or head of IR. Welcome, all of you. Head of R&D? R&DE, yes. Okay, yes, good. And so maybe give us an introduction about ProKidney for those who are less familiar with the story. What you're working on, what you're trying to achieve, what milestones we can expect over the next six to 12 months. Yeah. Sounds good, Andrew. And thanks for inviting us to the meeting. So ProKIDNEY is a company that's based in the U.S. We've got the majority of our employees in North Carolina. We have 250 employees. is aligned, I think, to a single purpose, and that single purpose is to help patients who've got diabetes and advanced chronic kidney disease to delay the onset of dialysis or the need for a transplant. We have a product, a single product. It's an autologous cell therapy. It's called RuparinCell. And we are fortunate enough to be well into our Phase III clinical study. On the background of good Phase II data, we finished enrollment. We finished recruitment in August. We anticipate finishing enrollment in Q1. And we expect an accelerated approval readout on a surrogate endpoint in Q2 of 2027. Perfect. And so maybe to level set the market opportunity, remind us the drugs approved for non-dialysis, type 2 diabetes, patients with non-dialysis KD, stage 3, 4B, or stage 3B, 4. How big is the population? What drugs are currently used at the moment? So the population just in the U.S. alone, there are about a million patients who've got advanced chronic kidney disease. That's late stage 3b or stage 4 chronic kidney diseases. And those million patients today have seen significant advances in the treatment of diabetic kidney disease over the last five years. And so right now, if you're treating a physician, you've got four pillars of therapeutic options that you could choose from. The older drugs are renin-angiotensin system inhibitors, ACE inhibitors and ARBs, for example. SGLT2 inhibitors are now approved. We've got non-steroidal MRAs and GLP-1s. So definitely a forward advance in how we treat patients who have chronic kidney disease and diabetes. But we also understand, and this is consistent across all those products and all the clinical data that's behind them, is that some patients continue to progress. And if you look at the data from each trial, there is a residual risk. And that residual risk is shown by the fact that the risk of developing a kidney related event or a cardiovascular event is still greater than the benefit that you see with the drug. So that speaks to the residual risk. Where we think we really fit in is knowing that some of these patients continue to progress and will end up on dialysis at some point in time. We're really there, we're positioning our therapy for those patients who are on standard of care and continue to progress, and that market is going to be a sub-fraction of the one million, but we still believe it's going to a substantial market. As a one- to two-time cell therapy, it's not a chronic therapy, to be clear. That's correct, Andrew, and so very good point there. All the other agents I mentioned, patients have to wake up every day and take those medications. If you're a diabetic with chronic kidney disease and your GFR is around 30, then you often have multiple comorbidities. You're often on a lipid-lowering agent, maybe multiple antihypertensives, maybe something to control edema, vitamin D, maybe an oral iron drug. I can go on. The average might be 8 to 10 to 12 drugs on a daily basis. With roparin cell, you get two injections, so you get one injection after the product is made, and three months later, you're getting an injection in the other kidney. First is in the biopsied kidney, and the other injections in the contralateral. Understood. What's the latest on your payer work? Because when I think cell therapy, you could price it very high. This is also a million patient population. And so what does it take to get a billion in peak sales in terms of price? Yeah, I'm going to ask James to have a go at that answer. James, if you don't mind. Sure. Yeah, so I think when we think about pricing, we can think about it from a couple of different perspectives. First is the value, the potential value that real parent cell could bring to the U.S. health care system. So dialysis costs the U!S. healthcare system for patients that are covered by Medicare $100,000 annually. And for patients who are covered, um, by private payers, it can cost two or more times that amount. So one way to think about it is for every year where a parent cell is able to stabilize kidney function and keep patients off of dialysis, that could deliver $200,000 of value or savings to the U.S. health care system. A couple of other ways to think about it are just by recent comps. So other recently launched cell therapies have launched in the $400,000 to $500,000 range. And also other recently launched treatments for other kidney diseases, Igans, an example, have also launched in the $400,000 to $500,000 range, and that's an annual cost. So that would likely be a lifetime annual cost going forward. So if you look at those, both the figures I gave you, which is potential savings to the U.S. healthcare system, as well as comps, you can start to narrow in on what pricing might look like thanks and if I could if you don't mind just James to add on something like that just given the fact that we're in the UK I will say that dialysis costs a lot of money wherever you look in across the world there are some countries like the US that's definitely the top tier of what's paid for dialysis but there are other countries some some countries in Europe that actually pay more than what the US pays for dialyses and a lot of countries that pay less as well I'll also say that just to put the patient patient forward here to dialysis has a huge impact on patients many patients go to dialysus three times per week most end up stopping to work because they can't go to Dialysis and continue to work many of them have out-of-pocket costs many require caretakers which often turns out to be a spouse or a daughter or son and then they're out of work so the impact on society is far more than just what the payer pays for a product. Makes sense. Makes sense, and so recently you, at ASN, the kidney conference, you shared some interesting data to help explain the mechanism of repair and sell, so can you kind of give us the key takeaways? Yeah, yeah, absolutely. So at ASM, we had seven non-clinical presentations, including an oral presentation, four of those were on our new mechanism of action work, and three on drug product characterization. So across all of our different CKD translational models spanning from in vitro, ex vivo, as well as rodent models, what we're observing in all of these different models is an attenuation of oxidative damage, metabolic dysregulation, pro-inflammatory signaling to promote functional stabilization of both endothelial cells, cells comprising the blood vessels, as well as epithelial cells, cells comprising the tubules. What we're observing in our rodent models is rilparencel after being injected into the kidney cortex. It's engrafting most consistently at the highest density in the subcapsular region. But the effects that we're seeing are more systemic, indicative of a paracrine mechanism. So the cells that the fact of rilparancel secreting is going into circulation and promoting more systemic therapeutic response. Great. And so let's talk about your ongoing pivotal trial. Like you said, the first readout in Q2 of next year is for an accelerated approval based on EGFR. So remind us how you powered the study on both the drug versus sham side of things. So we made some assumptions, as you always do when you're powering a study. So we assumed in the sham group of a 3 mL per minute decline in kidney function on an annual basis. We drew that information largely from a meta-analysis, which included well over 100,000 patients. The treatment effect that we're assuming with parent cell is a decline in kidney function of 1.5 mLs per minute per year. That's a little bit higher than what we've seen in one of our phase two trials, but we're making some very conservative estimates here. In this power assumption, we're seeing a benefit of 1 .5 mls per minute delta between the two groups. In a Phase II trial that we presented last year, we saw a 4.5 ml per minute difference between the two groups. So very conservative assumptions. The study is powered using the assumptions I just outlined at 80 percent to detect that 1.5ml per minute. Male Speaker 1 80 percent. And based on that Phase II data, the FDA gave you guys an RMAC designation. It wasn't, I don't think there was a, was there a sham? Sorry. Or was it open label? So the, there was no sham involved in the RMAT designation. So the RMat designation is really based upon, you need to have a product that's a gene therapy or cell therapy essentially. You need to be treating a disease or condition where you can have an impact on the cure or substantially change the outcome of that condition. and you need to have preliminary data. And the preliminary data that we used, you're right, Andrew, has come from the Phase II data, originally from the 002 data, not the 007 data. And the 0022 data is where we saw a big impact on patients with significant and advanced chronic illness. Okay. And so one more time, as you powered us for that, the drug reduces by 1.5 annualized annualized on the EGFR slope. In the prior phase 2, you saw something better than that, which is actually a less negative value. I always have to rethink this every time. But the point is, it was a conservative assumption on the drug side. On the sham side, you just said 3.0. How did you kind of model off of the sham? Yeah, that was based upon a Leslie Inker meta-analysis in nature medicine. And in that meta-analysis, I think of over 180,000 people with diabetes and chronic kidney disease. There was an average decline of 3 mLs per minute. Now what we've seen in our other phase two, just to be clear, other two phase two studies, is we saw a greater decline in untreated patients than 3 mls per minute, we saw decline in the range of 5 to 6. Now there's a couple of reasons why that might, why we might be seeing a greater decline in our Phase 2 population in the untreated patients. We speculate that physicians are treating patients who are already progressing. They're already on the best standard of care, and it's those patients that continue to progress that demonstrate that unmet need that are being picked by physicians to enroll in our Phase 3 program. I see. So, like, one difference between the Phase 2 and Phase 3 is maybe these patients are More phase three patients are technically on standard of care. So rather than five to six, maybe it's closer to three is your point. They might be, but actually we believe that even in our phase three, like we saw in our phase two, that it's the patients who are progressing are at greatest risk that the physicians are choosing to enroll in the study because standard of career doesn't seem to be working for them. Okay. And just more of a technicality question. And I think the phase three has enrolled, is it over 300 patients at the moment? The phase three trial has enrolled more than that, actually. So we, just to give some perspective, we have already enrolled the 320 patients needed for the accelerated approval readout. And we continue to enroll more patients based upon patients that were screened up until early August. So we anticipate the overall total population to be included in the study to be well north of 500 patients. Makes sense. For the accelerated approval analysis, it will be on that 320. Correct. And furthermore, will the analysis be based on that group or the subset of patients who are both biopsy and actually treated? And what do you anticipate that number to be? Yes. So the 320 includes patients who received at least one injection. Oh, okay. Yeah. So that's the 320. That's what's going to be included in the accelerated approval readout. In the confirmatory readout, that includes everyone, which will be north of 500 patients. Very clear. And have there been any changes in the formulation or the manufacturing side between phase 2 and phase 3 as I think about you trying to replicate what you saw in phase 2? So, there was a difference in manufacturing, slight difference going from one of our Phase II studies to the 007 study. We actually changed from a fresh product to a cryopreserved product. We made sure that the product that we were making was essentially the same product. So that product was used in 007. That cryopreferred process is what we're also using in our Phase III program. Got it. You mentioned these 320 patients, at least one injection. What proportion could have two injections? Would two get you better efficacy than one, for instance? We think two gets us better efficacy because we're injecting into the other kidney for the second one. The dropout between first injection and second injection is less than 3%. There's very little dropout going from first injection to second injection. I see. So 97% of patients generally should have both injections. Okay, very good. And on the safety side, after efficacy is pretty clear, on the safety front, what kind of special AEs are you specifically looking for? Have you seen any SAEs on a blinded basis? So, of course, in phase three, I'm blinded to everything that's going on. So I do see safety events that come in. We're specifically interested in safety events associated with the kidney biopsy because this is not a normal procedure, even Even though it's frequently done in the kidney space, we're asking these patients to do this for the study. And then we inject them twice. And so what we're looking for is any complication related to bleeding or infection specifically, right? As long as other complications, but those areas are where we're specifically looking. And then if there's any off-target effects, which we haven't seen. So we do see some bleeding complications, no more than what you typically see with a standard kidney biopsy. seen very rarely a local hematoma form around the kidney injection that's a very unusual event that happens with us and then in general the safety profile looks pretty good outside of you know including though including the bleeding event oh okay and can you remind me in phase two did you see any kind of severe events and do you expect that in phase three we're we always this population is going to have serious adverse adverse events no matter what you're doing to them just because they're they're sick they've got lots of comorbidities we're not seeing anything unusual in the SAE very clear okay so to wrap things up the data sets in q2 can you give us a teaser what you plan to share in the top line release how much data would we be getting well I can tell you that I'd love to sit here and say that I'll share everything that will share everything but we can't do that so we've we've got we've bought to work with regulators but but what we can see is that for companies that are releasing interim data that's associated with accelerated approval it's typically top line efficacy so maybe some secondary a secondary endpoint of interest but the primary efficacy for sure and then an overall assessment of safety but the details of which probably won't come out until ASN Kidney Week, which is later on in 2027, and we'd hope to get a simultaneous publication as well with that, where all the details will be shared. I see. And let's just say when the ASN 2027 happens in November, where we get more details, could that be the time where, as we talk about the next step of this trial, because right now it's accelerated pre-approval based on EGFR, but you also have a time to composite events for full approval. Could we get a cut of that actually? So again, I'd love to share that, but I don't think we can. So any time we take a peek at that type of data, then we burn some alpha in doing so. So we have no intent at looking at confirmatory events based on study group until we actually hit that 122 events, which would be the number we're looking for for the confirmatory number. And those events, what exactly are those, to be clear? Yeah, so it's a time to composite, which is typical for this type of study, and it's time to the first of the following, greater than a 40 percent decrease in EGFR, a sustained EGFR at less than 15, new onset chronic dialysis, a transplant, or renal and cardiovascular death. And just given the patient population that we're seeing, by far and away the greatest number of events that we are seeing are those related directly to EGF-R, which gives us a lot of confidence that the EG-R slope data that we'll see in Q2 of 27 is going to translate directly into any event benefit we'll see in the confirmatory readout. Understood. And you just mentioned discontinuation rates should be very low. We're seeing very little discontinuation rate between first and second injection. And even after second injection, the discontinuation raise is pretty slow. It's pretty low. Keep in mind that they're not having to take any medications or any drugs after the second injection They're just coming back for the routine follow-up. Right. And so that data set, EGFR, will be in Q2 of next year. The BLA filing, is it now early 2028? Yeah. The question would be why these many months? Why does it take so long? So there's a little bit of work to do in sort of on the clinical side to package everything up for the BLA submission. Now, I think we'll actually be ready on the clinical side earlier than Q1, 2028. What we've actually recognized recently is because of the increase in demand, essentially, the recruitment that came in over the spring and summer into the study, we wanted to make sure that everyone that was eligible could get into the trial. That pushed out our enrollment from Q4 of this year to Q1 of next year. That means our manufacturing facility is still making product in Q1. That pushes out their timelines. So they can't do some, you know, inspection-ready modifications to our site, some slight changes to the site to make it ready for inspection. They can't some of the final process validation work that needs to get done, and that's why it's pushed out into Q1 2028, which is, you know, I still think reasonably aggressive for the amount of work that needs to get done. Understood. And going back to the confirmatory, so I forgot to mention that data set is second half of 2029. What kind of hazard ratio are you expecting? So we assumed a difference between the two groups of essentially a hazard ratio of 0.6 between the 2 groups. That would be powered at 80% to detect that hazard ratio. I will say that the second half of 2029 is based upon an assumption of an event rate somewhere between 10 and 12 events per 100 patient years. We took that data from global studies, which included U.S. patients and included patients from Europe and Asia. It's possible that because we're including U. S. patients primarily in this study that we may see a higher event rate, and therefore less time to get to those 122 events. Thanks. So as we look fast forward a little bit as you're kind of filing for this product, how are you preparing on the manufacturing front? Ultimately, how many doses per year do you think you'll be able to provide with your manufacturing? Yeah, we actually just released a little Bit of Information on this recently, James. Do you mind talking about our capacity when we launch? Yeah, sure. So right now, first of all, we own all of our own manufacturing. We manufacture all the product for a Phase 3. in the same manufacturing facility that we've manufactured all the products for all of our clinical studies. And we have the ability to implant a launch from that same facility. At launch, we expect that facility that we've been manufacturing in to be able to manufacture 350 doses or products for 350 patients annually. We've also purchased in an adjacent building we've also built in an adjacent building that we also own the first manufacturing facility that can also manufacture up to 500 product in a year now the construction on that is effectively done, we've still got some work to do on tech transfer and some other things, so that will come online likely after launch maybe about a year after launch, so as we think about building out you know our capacity will be 350 at launch 500 about a year later in addition in that that other building that we just started to build out in we have other um we have additional space where we can continue to build up additional manufacturing rooms and then that that additional space coupled with the potential to look at you know potentially working um other geographic areas potentially working with CDMOs, we think we can get to 3,000 in a few years. Great. Andrew, that's well less than what number of patients who would need product, assuming that we're successful. So that's our current plans. So for us to really scale, based upon really good data, for us really scale we'd need to dedicate some investment, whether that's dilutive or whether that with partners or whether that through debt or some other mechanism to actually scale up where we can actually you know treat more patients and help more patients in total. Okay and then very last question in the last 30 seconds let's just say you did succeed here do you plan to move upstream or with this product or what what's next? So so right now we're focused solely on the advanced diabetic chronic kidney disease market it is so big that I don't want to take focus away from us doing a good job thank you very much appreciate the updates good luck on the data readout next year and thanks everyone for listening
- Company
- PROKIDNEY CORP
- Keywords
- PROKIDNEY CORP